Results With Additional Use of SP 54 in Percutaneous Transluminal Angioplasty

  • L. Horváth
  • K. Fendler
  • I. Illés
Conference paper


The idea of using sulfated polyanions — such as SP 54 (Benechemie, Munich) — was prompted by several factors. First of all, it is well-known that intravascular thrombi may be dissolved by natural human fibrinolytic activity. The stimulation of this process has been widely used for a long time in the form of low-dose subcutaneous heparin therapy in major surgery. But in this case the use of heparin serves other purposes too. Depending on their molecular compounds heparin and heparin-like drugs may stimulate fibrinolytic activity [1]. When this was investigated it was found that even old clots can be dissolved if they are not organized [2, 3]. So what would happen during and following percutaneous transluminal angioplasty (PTA) if we purposefully stimulated the fibrinolytic enzyme system? SP 54 as a sulfated polyanion has seemed a suitable substance to use in combination with PTA. Among members of the sulfated polyanion group, the capacity to activate the fibrinolytic system increases with the degree of depolymerization. Being a compound with a very low molecular weight, SP 54 shows the optimum effects; it develops no more than traces of anticoagulant activity, thus achieving adequate therapeutic mobilization and reactivation of the physiological enzyme system with negligible effects on blood coagulation [4]. And it does not involve hypocoagulemia with the dangerous tendency to hemorrhage. The optimum single dose of SP 54 is 1–2 mg/kg. A peak in the fibrinolytic action develops after 30–60 min following intravenous administration of SP 54. With intramuscular injection the peak of fibrinolytic activation occurs 1–2 h later, decreases in the next 4–6 h and is still measurable even after 24 h. An increase in the fibrinolytic activity of about 300% can be achieved using this drug. Its other effects (lipolysis, reduction of blood viscosity, antisludging effect, antiaggregation effect, etc.) are favorable in atherosclerotic diseases.


Fibrinolytic Activity Sulfated Polyanion Antiaggregation Effect Intravascular Thrombus Cumulative Patency Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Halse T, Philipp K, Ruf F (1950) Tierexperimentelle Untersuchung über intravasale Thrombolyse mit Heparin und Thrombocid. Langenbecks Arch Chir 263:459.CrossRefGoogle Scholar
  2. 2.
    Gottlob R, Blümel G (1969) Experimentelle Grundlagen der Lysierbarkeit alter Gerinnsel. In: Müller-Wieland K (ed) Fibrinolyse-Therapie. Schattauer, Stuttgart.Google Scholar
  3. 3.
    Lübcke P, Weber J, Bartscher U (1979) Lysierbarkeit und Frischhaltephänomen von akuten und älteren Phlebothrombosen unter Streptokinase-Einfluß. Herz Kreisl 11:126.Google Scholar
  4. 4.
    Weyer H, Muth HW (1973) Zur Therapie mit dem sulfatierten Polyanion SP 54. Med Welt 24:800.PubMedGoogle Scholar
  5. 5.
    Horváth L (1980) Percutaneous transluminal angioplasty: importance of anticoagulant and fibrinolytic drugs. Am J Roentgenol 135:951.Google Scholar
  6. 6.
    Horváth L, Fiegler M (1982) Treatment of a subclvian stenosis with perorally given fibrinolytic drug and by percutaneous transluminal angioplasty (in Hungarian). Orv Hetil 123:1051.PubMedGoogle Scholar
  7. 7.
    Luebke P, Weber J (1980) Delayed fibrinolysis of venous thrombi in pelvic veins and vena cava. In: May R, Weber J (eds) Pelvic and abdominal veins: progress in diagnostics and therapy. International Congress Series No. 550. Excerpta Medica, Amsterdam, p 345.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • L. Horváth
  • K. Fendler
  • I. Illés

There are no affiliations available

Personalised recommendations